Tufts CSDD Patient Engagement Survey

The era of big pharma as product-first companies must end, as services become the larger priority.

To rebuild trust, companies should focus on transparent, neutral content incorporating medical expertise and regularly seeking HCP feedback.

Agency will be reorganizing field force and compliance functions.

EU proposal focuses on a subset of underserved rare diseases—exploring the gaps in those conditions for which there is no approved treatment option.

Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.

Panel at recent Talk Health event at Le Méridien, in Philadelphia, PA, on September 11th, 2023, focused on what success looks like in audio from a publisher, vendor, and HCP perspectives.